Stock analysts at William Blair boosted their Q4 2025 EPS estimates for shares of Global Industrial in a research report ...

Stock analysts at William Blair dropped their Q1 2025 earnings per share estimates for shares of Verisk Analytics in a ...

We recently published a list of 8 Worst Performing Mutual Funds in 2024. In this article, we are going to take a look at ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report). The ...

In a report released today, Myles Minter from William Blair reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report). The ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

For Q1 2025, Insulet forecasts revenue growth between 22% and 25%, with U.S. Omnipod sales increasing by 21% % to 24%.